Karyopharm 2025 Q2 Earnings Sharp Earnings Drop Amid Persistent Losses

Karyopharm (KPTI) reported its Q2 2025 earnings on August 11, 2025. The company missed expectations with a significant drop in both revenue and profitability.

Karyopharm’s Q2 revenue of $37.93 million declined by 11.4% compared to $42.79 million in the same period of 2024. The performance was driven by product revenue, which stood at $29.68 million, while license and other revenue contributed $8.25 million. Despite a strong commercial performance, the company swung to a loss of $4.32 per share, a 291.2% negative change from a profit of $2.26 per share in the prior-year quarter. The net loss for the quarter reached $37.25 million, a 256.6% deterioration from a net income of $23.79 million in 2024 Q2. The company has now recorded losses for 11 consecutive years in the same fiscal period, signaling ongoing financial challenges.

Karyopharm’s stock has seen a steep decline post-earnings, with a 5.75% drop on the latest trading day, a 6.22% drop over the week, and a 24.60% drop month-to-date. The performance of the stock following its earnings has been underwhelming, with a 30-day average return of -26.4% over the past three years, underperforming the S&P 500 by 25.4%. The maximum drawdown reached 61.1%, underscoring the stock’s high volatility and risks.

Richard A. Paulson, CEO, highlighted the company’s continued progress in key Phase III trials, including the completion of patient enrollment in the SENTRY trial for myelofibrosis. He emphasized the potential for selinexor plus ruxolitinib to redefine treatment in the myelofibrosis space. Addressing liquidity concerns, Paulson noted that the company is actively engaging with lenders and advisors to enhance liquidity and prepare for near-term debt obligations. He also pointed to two pivotal Phase III readouts expected within the next 12 months, which could significantly impact the company’s long-term prospects.

For 2025, Karyopharm guided for total revenue between $140 million and $155 million, with U.S. XPOVIO net product revenue projected at $110 million to $120 million. R&D and SG&A expenses are expected to range between $240 million and $250 million. The company currently expects its liquidity to fund operations through October 2025 and into January 2026, excluding debt maturities. Karyopharm aims to explore strategic and financing alternatives to extend its cash runway and maximize shareholder value.

Additional News
In the three weeks following Karyopharm’s earnings report, several notable non-earnings-related developments emerged. Ogun State Police arrested a motorcyclist in possession of three human skulls, sparking public outcry over the incident. A significant political event occurred as Jigawa State Governor Umar Namadi presented the All Progressives Congress flag to a by-election candidate, signaling active political engagement ahead of upcoming contests. On the economic front, Nigeria’s federal government announced it had generated N5.21 trillion from oil sales in the first half of 2025, highlighting the continued importance of the oil sector in the national economy. These events reflect ongoing social, political, and economic developments in Nigeria.